Anika Therapeutics Inc (ANIK) Stock Analysis

AI analysis of Anika Therapeutics Inc (ANIK)

Buy

Anika Therapeutics Inc is a good buy right now, with a current price of $19.41 and a recent analyst price target of $21, suggesting a potential upside of approximately 8.1%. The stock has shown a significant year-to-date change of +107.59%, indicating strong momentum. However, the RSI is at 25.63, suggesting it is oversold, which could present a buying opportunity. The main risk is the negative net income reported in the last quarter at -5.06 million USD, which indicates ongoing financial challenges that investors should monitor closely.

Analyst Ratings (3)

-21.57% Downside

Buy

2 Buy

1 Hold

0 Sell

Current: 20.40

Low

16.00

Average

16.00

High

16.00

B. Riley

Buy

$21

2026-07-30

B. Riley

2026-07-30

Price Target

$21

Buy

B. Riley

Buy

$18

2026-02-27

B. Riley

2026-02-27

Price Target

$18

Buy

Barrington

Outperform

$17

2026-02-27

Barrington

2026-02-27

Price Target

$17

Outperform

Barrington

Outperform

$16

2025-11-06

Barrington

2025-11-06

Price Target

$16

Outperform

Barrington

Outperform

$19

2025-05-12

Barrington

2025-05-12

Price Target

$19

Outperform

See All Ratings

Valuation Metrics

The current forward P/E ratio for Anika Therapeutics Inc (ANIK) is 22.08, compared to its 5-year average forward P/E of 98.27.

Forward P/E

Fair

5Y Average P/E

98.27

Current P/E

22.08

Overvalued

592.96

Undervalued

-396.41

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-55.30

Current EV/EBITDA

12.71

Overvalued

340.57

Undervalued

-451.18

Forward P/S

Fair

5Y Average P/S

2.05

Current P/S

2.13

Overvalued

2.60

Undervalued

1.50

Alphio AI Price Scenarios for ANIK

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ANIK

$10.31

Scenario price

B

Base

Base · 50%ANIK

$9.76

Scenario price

B

Bear

Bear · 25%ANIK

$8.10

Scenario price

Whales holding ANIK

C

Caligan Partners, LP

+ HoldingANIK

-17.44%

3M Return

ANIK FAQ — answered by Alphio AI

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Anika Therapeutics Inc is a good buy right now, with a current price of $19.41 and a recent analyst price target of $21, suggesting a potential upside of approximately 8.1%. The stock has shown a significant year-to-date change of +107.59%, indicating strong momentum. However, the RSI is at 25.63, suggesting it is oversold, which could present a buying opportunity. The main risk is the negative net income reported in the last quarter at -5.06 million USD, which indicates ongoing financial challenges that investors should monitor closely.

3 analysts cover ANIK: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 16.00.